Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead.

Jena, R; Vishwas, S; Kumar, R; Kaur, J; Khursheed, R; Gulati, M; Singh, TG; Vanathi, BM; Alam, A; Kumar, B; Chaitanya, MVNL; Gupta, S; Negi, P; Pandey, NK; Bhatt, S; Gupta, G; Chellappan, DK; Oliver, BG; Dua, K; Singh, SK

Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead.

Jena, R Vishwas, S Kumar, R Kaur, J Khursheed, R Gulati, M Singh, TG Vanathi, BM Alam, A Kumar, B Chaitanya, MVNL Gupta, S Negi, P Pandey, NK Bhatt, S Gupta, G Chellappan, DK Oliver, BG Dua, K

Singh, SK

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Eur J Pharmacol, 2022, pp. 175173
Issue Date:: 2022-08-05

Closed Access

	Filename	Description	Size
	HIV_CRISPR:CAS Technology.pdf	Published version	6.55 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Jena, R
dc.contributor.author	Vishwas, S
dc.contributor.author	Kumar, R
dc.contributor.author	Kaur, J
dc.contributor.author	Khursheed, R
dc.contributor.author	Gulati, M
dc.contributor.author	Singh, TG
dc.contributor.author	Vanathi, BM
dc.contributor.author	Alam, A
dc.contributor.author	Kumar, B
dc.contributor.author	Chaitanya, MVNL
dc.contributor.author	Gupta, S
dc.contributor.author	Negi, P
dc.contributor.author	Pandey, NK
dc.contributor.author	Bhatt, S
dc.contributor.author	Gupta, G
dc.contributor.author	Chellappan, DK
dc.contributor.author	Oliver, BG
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Singh, SK
dc.date.accessioned	2022-08-11T12:22:18Z
dc.date.available	2022-07-21
dc.date.available	2022-08-11T12:22:18Z
dc.date.issued	2022-08-05
dc.identifier.citation	Eur J Pharmacol, 2022, pp. 175173
dc.identifier.issn	0014-2999
dc.identifier.issn	1879-0712
dc.identifier.uri	http://hdl.handle.net/10453/159964
dc.description.abstract	Advances in biotechnology have led to improving human health with number of novel approaches to mitigate life-threatening diseases such as human immunodeficiency virus (HIV) infection, cancer, and neurodegenerative diseases. In the case of HIV, the damage caused by the retrovirus to the immune system leads to opportunistic infection as well as an elevated risk of autoimmune disease and cancer. Furthermore, clinical symptoms associated with the virus itself may arise. Antiretroviral drug therapy using reverse transcriptase inhibitors, protease inhibitors, fusion inhibitor, chemokine receptor 5 antagonist and integrase strand transfer inhibitors have shown promising results in treating HIV infection and available in market in the form of various dosage forms. However, they are unable to completely cure the disease because of complexity in pathogenesis of HIV. In addition, these drugs have some limitations of poor solubility, permeability or, poor receptor binding capacity. To overcome these drawbacks, many novel drug delivery systems for the drugs belonging to above mentioned categories have been developed. The possibility of treating HIV infection using CRISPR-Cas9 gene editing has been found in 2015. This provided a new area of research to the scientists who are working towards alternative treatment strategies for HIV infections. The present article describes about various treatment strategies used to treat HIV infections with special emphasis on the role of CRISPR/Cas9 gene-based technology. The potential benefits of specific epigenetic modification in the c-c chemokine receptor 5 gene (CCR5) via various delivery methods are also highlighted.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Eur J Pharmacol
dc.relation.isbasedon	10.1016/j.ejphar.2022.175173
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0801 Artificial Intelligence and Image Processing, 1115 Pharmacology and Pharmaceutical Sciences, 1701 Psychology, 1702 Cognitive Sciences
dc.subject.classification	Behavioral Science & Comparative Psychology
dc.subject.classification	Pharmacology & Pharmacy
dc.title	Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead.
dc.type	Journal Article
utslib.location.activity	Netherlands
utslib.for	0801 Artificial Intelligence and Image Processing
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1701 Psychology
utslib.for	1702 Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-08-11T12:22:14Z
pubs.publication-status	Published online

Abstract:

Advances in biotechnology have led to improving human health with number of novel approaches to mitigate life-threatening diseases such as human immunodeficiency virus (HIV) infection, cancer, and neurodegenerative diseases. In the case of HIV, the damage caused by the retrovirus to the immune system leads to opportunistic infection as well as an elevated risk of autoimmune disease and cancer. Furthermore, clinical symptoms associated with the virus itself may arise. Antiretroviral drug therapy using reverse transcriptase inhibitors, protease inhibitors, fusion inhibitor, chemokine receptor 5 antagonist and integrase strand transfer inhibitors have shown promising results in treating HIV infection and available in market in the form of various dosage forms. However, they are unable to completely cure the disease because of complexity in pathogenesis of HIV. In addition, these drugs have some limitations of poor solubility, permeability or, poor receptor binding capacity. To overcome these drawbacks, many novel drug delivery systems for the drugs belonging to above mentioned categories have been developed. The possibility of treating HIV infection using CRISPR-Cas9 gene editing has been found in 2015. This provided a new area of research to the scientists who are working towards alternative treatment strategies for HIV infections. The present article describes about various treatment strategies used to treat HIV infections with special emphasis on the role of CRISPR/Cas9 gene-based technology. The potential benefits of specific epigenetic modification in the c-c chemokine receptor 5 gene (CCR5) via various delivery methods are also highlighted.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/159964